Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 130Lymphoma, Large B-Cell, Diffuse 101Lymphoma, Follicular 90Leukemia, Lymphocytic, Chronic, B-Cell 82Lymphoma 63Lymphoma, B-Cell 43Recurrence 31Lymphoma, Mantle-Cell 30Lymphoma, B-Cell, Marginal Zone 23Neoplasms 22Leukemia 10Hematologic Diseases 10Lymphatic Diseases 8Multiple Myeloma 7Immunoproliferative Disorders 6Hematologic Neoplasms 6Waldenstrom Macroglobulinemia 5Lymphoproliferative Disorders 5Leukemia, B-Cell 5Arthritis, Rheumatoid 5Hodgkin Disease 4Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Immune System Diseases 3Dendritic Cell Sarcoma, Interdigitating 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2

Interventions

ibrutinib 3Rituximab 3Cyclophosphamide 3Bortezomib 3tetulomab tetraxetan lu-177 2ponatinib 2fludarabine 2cobomarsen 2Vorinostat 2Lutetium 2enzalutamide 1durvalumab 1cirmtuzumab 1acalabrutinib 1Vincristine 1Prednisone 1Lutetium-177 1Lenalidomide 1KW-2478 1Imatinib Mesylate 1Ifosfamide 1Hsp90 inhibitor KU757 1Etoposide 1Doxorubicin 1Carboplatin 1CA-4948 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Immune System Diseases × Rituximab × Clear all
NCT02733042 2023-11-18

FUSION NHL 001

Celgene

Phase 1/2 Completed
106 enrolled 48 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡